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Background: Rapid and accurate diagnosis of mucopolysaccharidoses (MPS) is still a challenge due to poor access 
to screening and diagnostic methods and to their extensive clinical heterogeneity. The aim of this work is to per-
form laboratory biochemical testing for confirming the diagnosis of mucopolysaccharidosis (MPS) for the first 
time in Morocco. 
Methods: Over a period of twelve months, 88 patients suspected of having Mucopolysaccharidosis (MPS) were re-
ferred to our laboratory. Quantitative and qualitative urine glycosaminoglycan (GAG) analyses were performed, 
and enzyme activity was assayed on dried blood spots (DBS) using fluorogenic substrates. Enzyme activity was 
measured as normal, low, or undetectable. 
Results: Of the 88 patients studied, 26 were confirmed to have MPS; 19 MPS I (Hurler syndrome; OMIM 
#607014/Hurler-Scheie syndrome; OMIM #607015), 2 MPS II (Hunter syndrome; OMIM #309900), 2 MPS IIIA 
(Sanfilippo syndrome; OMIM #252900), 1 MPS IIIB (Sanfilippo syndrome; OMIM #252920) and 2 MPS VI 
(Maroteaux-Lamy syndrome; OMIM #253200). Parental consanguinity was present in 80.76% of cases. Qualita-
tive urinary glycosaminoglycan (uGAGs) assays showed abnormal profiles in 31 cases, and further quantitative 
urinary GAG evaluation and Thin Layer Chromatography (TLC) provided important additional information 
about the likely MPS diagnosis. The final diagnosis was confirmed by specific enzyme activity analysis in the DBS 
samples. 
Conclusions: The present study shows that the adoption of combined urinary substrate analysis and enzyme as-
says using dried blood spots can facilitate such diagnosis, offer an important tool for an appropriate supporting 
care, and a specific therapy, when available. 
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High consanguinity, difficult access to accurate diag-
nostic tests, and costly therapies are all significant con-
tributors to the lysosomal disease burden. The adoption 
of combined urinary procedure and enzyme essays us-
ing dried blood spot can facilitate earlier diagnosis and 
consequent earlier consideration of therapeutic options 
and earlier counseling to affected families. The Muco-
polysaccharidosis (MPS) is a group of metabolic disor-
ders characterized by a deficiency in one of the lysoso-
mal enzymes necessary for the catabolism of glyco-
saminoglycans (GAGs), formerly known as mucopoly-
saccharides [1]. Deficiency of these enzymes leads to a 
widespread accumulation of undegraded or partially de-
graded GAGs in different tissues and to excessive ex-
cretion of these substances in urine [2]. 
The MPS subtypes have multi-systemic clinical mani-
festations of variable severity. In Morocco, obtaining an 
early clinical MPS diagnosis has historically been a 
challenge and patients have not been diagnosed until 
more advanced stages of the disease. Early diagnosis is 
of paramount importance for an optimum management 
of inborn errors and a better prognosis. There is no na-
tional protocol for newborn screening of inborn errors 
of metabolism in Morocco. Affordable, easy and accu-
rate testing of suspected patients is therefore fundamen-





MATERIALS AND METHODS 
 
This study included 88 Moroccan patients suspected of 
MPS who were referred to the Biochemical Laboratory 
in the Marrakech Faculty of Medicine by the pediatric 
departments of Mohamed VI University Hospital. The 
patient ages ranged from 9 months to 15.6 years (medi-
an, 8 years). Most of the patients referred were from 
consanguineous families (74%). 
The first step in our laboratory diagnosis of these pa-
tients suspected of having an MPS was the quantitative 
and qualitative analysis of urinary glycosaminoglycans 
(uGAGs) [3,4]. An early morning urine sample (10 -   
20 mL) was collected from each patient for the determi-
nation of GAGs using semi-quantitative, quantitative, 
and qualitative assays. Deficient enzyme activity testing 
was done using 60 - 70 µL of whole blood spotted on 
filter paper (Whatman-GE no. 903) and dried for 4 
hours at room temperature. Filter papers were stored at 
4°C in plastic containers. This algorithm for patient 
sample analysis is shown in Figure 1. 
This study was conducted in compliance with the rec-
ommendations of the Declaration of Helsinki and Good 
Clinical Practice (GCP) Guidelines. The study was ap-
proved by the Independent Ethics Committee of Marra-
kech Hospital University, and consent was obtained 
from patients and/or their parents or guardians. 
 
Laboratory analysis of urinary glycosaminoglycans 
The GAG assay was the usual first step in making our 
biochemical diagnosis [5,6]. uGAGs remain stable at 
room temperature for up to 10 days, so urine samples do 
not need to be frozen for transport to the laboratory [7]. 
Both semi-quantitative (the GAG test) and quantitative, 
using dimethyl methylene blue (DMB), assays were 
used. 
 
Dimethyl methylene blue solution 
DMB solution was prepared according to the method 
described by Andrade et al. [7]. In a volumetric flask of 
1 L, 10.66 mg of DMB (research grade, purchased from 
Sigma-Aldrich, CAS: 931418-92-7) was added, with 
3.33 mL of ethanol (purchased from Merck, CAS: 64-
17-5), 1.33 g of sodium formate (purchased from 
Merck, CAS: 141-53-7), and 1.33 mL of formic acid 
(purchased from Sigma-Aldrich, CAS: 64-18-6). The 
pH value was adjusted to 3.75 by adding more concen-
trated acid or solid formate. The flask was filled up to   
1 L with distilled water. This solution has proven to be 
stable for at least 10 months at 5°C. A chondroitin 6-
sulfate solution was prepared at 100 mg/L in distilled 
water. The solution is stable for at least one year at 4°C, 
when stored in the dark. 
 
Semi quantitative and quantitative urinary glycos-
aminoglycans determination 
The GAG test was performed using a colorimetric 
method based on the color change produced by the 
complexes formed between DMB and GAGs [8,9]. The 
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DMB solution was transferred to transparent vials        
(2 mL), to which 50 µL of a centrifuged first morning 
urine was added. A high urine concentration of GAGs, 
which occurred in patients with MPS I, II and VI, was 
considered as a positive result (blue color changed to 
purple). A negative result was confirmed if the urinary 
GAG concentration was low (no color change). Finally, 
if the color of the GAG-tests changed to violet, it was 
considered as an inconclusive result. 
The quantitative determination of urinary GAGs was 
performed on all patient samples, even if a negative re-
action was observed in the first GAG test. It was per-
formed using ultraviolet-visible spectrophotometry. For 
the calibration curve, we constructed a series of dilu-
tions from a solution of chondroitin 6-sulphate: (100 mg 
/mL of water) by diluting 5, 10, 25, 50, and 100 µL in 
water to obtain a final volume of 500 µL. With the pa-
tient samples, 100 µL of urine were diluted in water to 
obtain a final volume of 500 µL. After the dilution, we 
added 2.5 mL of DMB. The readings were taken using 
the differences between the absorbance at 520 and 600 
nm [7,9]. Spectrophotometric measurements were re-
corded on a UV-visible 1601 Shimadzu spectrophotom-
eter (Shimadzu Co., Kyoto, Japan). If a particular urine 
sample was too diluted or concentrated, the volume of 
urine was increased or reduced, taking into account the 
appropriate dilution factor. Finally, the GAG concentra-
tion was calculated on the basis of creatinine values, de-
termined by an automated chemistry analyzer using the 
Jaffe method. The final GAG results were expressed in 
mg/mmol creatinine. To avoid erroneous results in the 
concentration of GAGs, all urine samples with a creati-
nine concentration of less than 20  mg/dL or more than 
200  mg/dL were recollected. 
Since the method of measuring total GAGs in urine is 
incapable of distinguishing between the different types 
of GAGs excreted and considering that several studies 
have reported that patients with MPS III, IV, and VII 
may have comparatively lower levels of GAGs, result-
ing in a false-negative result [4,10,11], a qualitative 
analysis of urinary GAGs was needed for the group and 
differential diagnosis of MPS patients, but all were fur-
ther confirmed by enzyme assays. 
 
Urinary GAG Isolation 
GAGs were isolated from urine by precipitation with 
cetylpyridinium chloride solution (CPC), (purchased 
from Sigma-Aldrich, CAS: 6004-24-6) using a modified 
Humbel method [12]. A thin layer chromatography 
(TLC) assay was used to identify the specific pattern of 
GAG excretion. The starting volume of urine was deter-
mined on the basis of GAG concentrations of creatinine; 
hence urine volumes used were between 1 and 6 mL. 
Urine was centrifuged at 2,000 rpm for 10 minutes at 
room temperature. The supernatant was added to the 
same volume of CPC solution, pH 4.8; the mixture was 
incubated for 30 minutes at 37°C in a water bath, fol-
lowed by a second centrifugation using the same condi-
tions. The supernatant was discarded. The tube was 
drained for 5 minutes by inversion on a filter paper in 
order to remove the remaining supernatant. The pellet 
was dissolved in 150 L of a 2 M lithium chloride (pur-
chased from Lobachemie, CAS: 7447-41-8) solution. 
Then, 800 L of absolute ethanol was added and a pi-
pette was used for mixing to carefully dissolve the 
GAGs. This solution was transferred to an Eppendorf 
tube and left for 5 minutes, and then the solution was 
centrifuged at 2,000 rpm for 10 minutes. The superna-
tant was aspirated and the resulting pellet was dried 
overnight. 
 
Thin layer chromatography GAG characterization 
The TLC conditions described by Humbel [13] were 
modified as follows: dried GAG pellets were dissolved 
in 20 L phenol red solution 0.05% (purchased from 
Sigma-Aldrich, CAS: 143-74-8). 
If the amount of precipitated GAGs was too elevated, 
the volume of 30 or 40 L phenol red solution was add-
ed; 8 L was applied on a TLC cellulose glass plates 
(20 x 20 cm, purchased from Merck 1.05716.0001). 
Starting with the origin, every 2 cm, six lines were 
drawn with a soft pencil. These indicated the borders for 
each solvent system; six TLC developing tanks were 
used. The samples were spotted on the TLC plate over a 
length of 1.5 cm, at 0.5 cm from each sample and ap-
proximately 2 cm from the lower edge and at least 1.3 
cm from the sides. Standards were prepared: 10 L of 
GAG standards, purchased from Sigma-Aldrich: Der-
matane sulfate (DS, CAS: 54328-33-5), Heparane sul-
fate (HS, CAS: 57459-72-0), Chondroitin sulfate (C4S, 
CAS: 39455-18-0 and C6S, CAS: 9082-07-9), and Ker-
atan sulfate (purchased from Glycofinechem, CAS: 
9056-36-4) at 1 mg/mL in 0.05 M Sodium hydroxide 
(NaOH) and extracted GAGs were dissolved in 20 L 
of red phenol solution (precipitated GAGs obtained as 
described above). Solvents were prepared just before 
the chromatography following the instructions given in 
Table 1. 
The plate was subsequently placed into six different 
tanks, which contained decreasing amounts of ethanol. 
One complete run required approximately 7 hours. The 
plate was allowed to dry overnight. Chromatograms 
were stained with 0.1% toluidine blue (purchased from 
Sigma-Aldrich, CAS: 92-31-9) in 70% ethanol/acetic 
acid (95:5) and destained with 1% acetic acid solution 
(purchased from Sigma-Aldrich, CAS: 64-19-7). The 
plate was allowed to dry overnight. 
 
Enzyme activity assays 
Enzyme activity assays are the gold standard for diag-
nosis confirmation and determination of the MPS types 
and subtypes. The diagnosis is based on specific enzy-
matic assays performed in plasma, leukocytes or fibro-
blasts. Recently, DBS samples have been used for these 
assays [14]. This approach offers several advantages, 
including a simple and expedited sample collection, 
minimal invasiveness, reduced sample volume, easy 
sample handling, storage for extended periods of time 
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and the possibility of using DBS samples for assaying 
the activity of any lysosomal enzyme. Fluorometric 
methods which had already been validated [15,16], 
were completed for the evaluation of α-iduronidase 
(MPS I) and arylsulfatase B (MPS VI). To evaluate 
iduronate-2-sulfatase (MPS II), we adapted the method 
of Voznyi et al. [17] as follows: 
 
Iduronidase assay in DBS samples (MPS I) 
Twenty microliters of sodium formate buffer (50 mmol/ 
L, pH 2.8) containing 0.3 µg/L of D-saccharic acid-1,4-
lactone (purchased from Sigma-Aldrich, CAS: 61278-
30-6) and 20 µL of water as elution liquid and 20 µL of 
2 mmol/L 4-methylumbelliferyl α-L-idopyranosiduronic 
acid, sodium salt (purchased from Toronto Research 
Chemicals INC, CAS: 89157-94-8) in distilled water as 
the substrate, were added to microtiter plates, together 
with a 3 mm-diameter punched circle from DBS       
(3.6 µL of blood). The microtiter plates were incubated 
for 20 hours at 37°C using an agitator (Heidolph Instru-
ments GmbH & Co. KG, Germany) at 600 rpm. The mi-
crotiter plates were allowed to stand for 30 minutes at 
room temperature, and 300 µL of ethylenediaminetetra-
acetic acid 0.13 mol/L, pH 11.3 (purchased from Sig-
ma-Aldrich, CAS: 107-15-3) was added to stop the re-
action. Blanks were treated as described above but the 
substrate solution and stop solution were added after in-
cubation. Finally, each sample was transferred into a 
cuvette and completed with stop solution up to 2 mL. 
Fluorescence (excitation: 365 nm; emission: 450 nm, 
cuvette volume: 1 mL) of the enzyme product 4-methyl-
umbelliferone (4-MU) (purchased from Sigma-Aldrich, 
CAS: 90-33-5) was measured with a Jasco FP-750 spec-
trofluorometer. The fluorescence readings were correct-
ed for blanks, and the results were compared with the 
fluorescence from a calibrator. A calibration curve was 
prepared using different dilutions of 4-MU standards (0 
- 500 µmol/L). Enzymatic activity was expressed as mi-
cromoles of substrate hydrolyzed per liter of blood per 
hour (µmol/L*h). 
 
Iduronate sulfatase assay in DBS samples (MPS II) 
To 1.5 mL test tubes containing 3 mm diameter punch-
ed circle (3.6 µL of blood), we added 50 µL of bovine 
serum albumin (BSA, purchased from Sigma-Aldrich, 
CAS: 9048-46-8) 0.2% as the elution liquid. After gen-
tle mixing for 30 minutes at 37°C, test tubes were cen-
trifuged at 2,000 rpm for 10 minutes at room tempera-
ture. In microtiter plates, we introduced 10 µL of super-
natant and we added 20 µL of 1.25 mmol/L 4-methyl-
umbelliferyl α-L-idopyranosiduronic acid 2-sulfate di-
sodium salt (purchased from Toronto Research Chemi-
cals INC, CAS: 1045020-74-3) previously dissolved in 
sodium acetate buffer (purchased from LOBA Chemie, 
CAS: 127-09-3) (0.1 mol/L, pH 5.0). The microtiter 
plates were incubated for 24 hours at 37°C using an agi-
tator at 600 rpm. After the incubation, we added 40 µL 
of phosphate citrate buffer (sodium phosphate dibasic 
anhydrous, purchased from Sigma-Aldrich, CAS: 7558-
79-4, and citric acid monohydrate, purchased from 
Ridel- de Haen, CAS: 5949-29-1) (0.2 mol/L, pH 4.5) 
and 10 µL of purified α-iduronidase from bovine testis 
(LEBT M2 purchased from Moscerdam substrates). The 
microtiter plates were incubated a second time for 24 
hours at 37°C using an agitator at 600 rpm. The microti-
ter plates were allowed to stand for 30 minutes at room 
temperature, and 200 µL of carbonate-bicarbonate buff-
er sodium (carbonate, purchased from Reacting, REF: 
3565, and sodium bicarbonate, purchased from Sigma-
Aldrich, CAS: 144-55-8) (0.5 mol/L, pH 10.5) were 
added to stop the reaction. Blanks were treated as 
described above but the substrate solution and stop 
solution were added at the end of second incubation. 
Finally, each sample was transferred into a cuvette and 
completed with a stop solution up to 2 mL. Fluores-
cence was read at excitation 360 nm and emission at 
450 nm for the enzyme product 4-MU. 
 
Arylsulfatase B assay in DBS samples (MPS VI) 
A 2-mm diameter filter paper was punched (2 µL of 
blood) with a standard paper punch and 45 µL of dis-
tilled water and 30 µL of 15 mmol/L lead acetate in so-
dium acetate buffer (50 mmol/L, pH 5.0) were added as 
the elution liquid and 75 µL of 10 mmol/L 4-methylum-
belliferyl-sulfate (purchased from Sigma-Aldrich, CAS: 
15220-11-8) in sodium acetate buffer (0.05 M, pH 5.0) 
as the substrate. The microtiter plates were incubated 
for 6 hours at 37°C using an agitator at 600 rpm. The 
microtiter plates were allowed to stand for 30 minutes at 
room temperature and 150 µL of glycine-sodium hy-
droxide buffer (glycine, purchased from Sigma-Aldrich, 
CAS: 56-40-6 and sodium hydroxide, purchased from 
Panreac, CE: 215-185-5) (85 mmol/L, pH 10.5) was 
added to stop the reaction. Blanks were treated as de-
scribed above but the substrate solution and stop solu-
tion were added after incubation. Finally, each sample 
was transferred into a cuvette and completed with a stop 
solution up to 2 mL. Fluorescence (excitation: 365 nm; 
emission: 450 nm, cuvette volume: 1 mL) of the en-
zyme product 4-MU was measured with a Jasco FP-750 
spectrofluorometer. 
As recommended, when arylsulfatase B or iduronate 
sulfatase activity was found to be low, a second sulfa-
tase (iduronate sulfatase or arylsulfatase B) was mea-
sured to rule out multiple sulfatase deficiencies. 
The specific enzyme essays for patients with Sanfilippo 
syndrome and for those suspected of Morquio syndrome 
were performed in referenced laboratories abroad since 






Analysis of 88 urine samples yielded 26 positive GAG 
test results, 5 inconclusive results, and 57 negative re-
sults. All patients with a negative GAG test showed 
quantitative GAG values within the normal range. Of 
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Table 1. Procedures for TLC separation of GAGs extracted from urine. 
 
Tanks Solvents (proportions by volume and masse) Elution time (min) 
I Calcium Acetate: 0.5 N Acetic Acid: Ethanol (3.36 g: 60 mL: 90 mL) 30 
II Calcium Acetate: 0.5 N Acetic Acid: Ethanol (6.74 g: 75 mL: 75 mL) 55 
III Calcium Acetate: 0.5 N Acetic Acid: Ethanol (6.74 g: 90 mL: 60 mL) 65 
IV Calcium Acetate: 0.5 N Acetic Acid: Ethanol (6.74 g: 105 mL: 45 mL) 75 
V Calcium Acetate: 0.5 N Acetic Acid: Ethanol (6.74 g: 120 mL: 30 mL) 80 
VI Calcium Acetate: 0.5 N Acetic Acid: Ethanol (6.74 g: 135 mL: 15 mL) 80 
 





those with inconclusive GAG tests, 1 of 5 showed quan-
titative GAG values slightly elevated, whereas all of 
those with positive GAG tests had an increased GAG 
concentration in urine. 
TLC was carried out for all patients with total GAG lev-
els strongly or slightly elevated, all those patients sus-
pected of MPS IV, even with a low urinary excretion of 
GAG (3 cases), and those patients exhibiting symptoms 
consistent with mucopolysaccharidosis, including the 
microlipidosis and several glycoprotein storage disor-
ders. 
All patients with increased GAG concentrations had a 
pathological profile on TLC corresponding to different 
GAGs excreted and were referred to a specific enzyme 
diagnosis. 
Measurement of enzyme activity in DBS was performed 
in those patients who had a specific pathologic chroma-
tographic pattern (n = 26) and those who were suspect-
ed clinically to have MPS IV (n = 3) even with normal 
levels of total urinary GAGs and no specific pattern on 
TLC. A summary of quantitative GAG analysis in all 
patients confirmed to have an MPS and their subsequent 
enzyme confirmations are shown in Table 2. Twenty-six 
patients from nineteen families were diagnosed with 
MPS I, II, III, and VI. The percentage of consanguine-
ous marriage among confirmed MPS cases was 80.76%. 
All patients were diagnosed after the age of 3 years ex-
cept for two patients (P18, P25), for whom the diagno-
sis was made at 9 months and 17 months following the 
confirmation of a sister’s diagnosis. 
The common disease-related symptoms in patients diag-
nosed with MPS I, II, and VI were short stature, multi-
ple joint contractures, inguinal/umbilical hernias, hepa-
tomegaly, mild to severe skeletal changes, coarse facial 
features, and developmental delay. The oldest patient 
with MPS III A (8.6 years) exhibited multiple symp-
toms including loss of speech; sleep disturbances, de-
mentia, hyperactivity, impulsivity and obstinacy, and 
seizures that started at the age of 8. Her sibling, (9 
months) only exhibited symptoms of frequent upper res-
piratory infections. The patient with MPS IIIB (4.9 
years), presented with speech delay, hyperactivity, ag-
gressiveness, sleep disturbances, mild hepatomegaly,
mild coarse facial features, and hypertrichosis. 
For patients clinically suspected of MPS IV, enzyme ac-
tivity testing of N-acetylgalactosamine-6-sulfate sulfa-
tase and β-galactosidase activities, essential in diagnos-
ing MPS IVA and IVB, respectively, was performed to 
rule out this diagnosis, based initially on clinical symp-
toms. 
In one case with GAG levels slightly elevated, TLC 
analysis showed strange spots not compatible with any 
of the MPS types (Figure 2, lane 5). As GAGs are pres-
ent also in bones and cartilages, their levels can be ele-
vated in other diseases affecting these tissues, such as 
mucolipidosis [18]. A diagnosis of mucolipidosis III 
was confirmed based on clinical and radiological find-
ings, and elevated activity of lysosomal enzymes (mea-
sured on DBS sample) including α-iduronidase and 
iduronate-2-sulfatase. Among patients with inconclu-
sive GAG test, three patients with GAG levels within 
normal ranges presented clinical similarities with diag-
nosed mucolipidosis III patient: short stature, multiple 
joint contractures, mild coarse facial features, and de-
velopmental delay. We performed a TLC analysis and 
found the same abnormal patterns (Figure 2, Lane 6).    
In the last infant with inconclusive GAG test, somatic 
features and GAG levels within normal ranges, a strong 
band was seen on TLC analysis, the position of which 
could not be confused with other MPS or mucolipidosis 
disorders (Figure 2, Lane 7). She is under investigation 





There is a growing body of evidence that early initiation 
of disease-specific therapy in MPS I, II, and VI leads to 
a substantial modification of the natural course of the 
disease. To achieve these goals, we are the first Moroc-
can/North African laboratory to invest in the diagnosis 
of mucopolysaccharidosis by enzymatic essays using 
dried blood spots. We proceeded by a simple, inexpen-
sive, and practical first line combined procedure. This 
approach was derived from a combination of pre-exist-
ing methods such as GAG tests, quantitative urinary 
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F1/P1 11.2 F + HS 90.90 3.3 - 13.7 
Alpha-L-
iduronidase 
0.1 (µmol/L*h) 2.1 - 11.7 MPS-I
F1/P2 12.3 M + HS 75.80 3.3 - 13.7 
Alpha-L-
iduronidase 
0.1 (µmol/L*h) 2.1 - 11.7 MPS-I
F2/P3 3.1 M + IH 117.83 9.5 - 25.7 
Alpha-L-
iduronidase 
0.0 (µmol/L*h) 2.1 - 11.7 MPS-I
F2/P4 7.4 F + IH 117.12 6.7 - 15.5 
Alpha-L-
iduronidase 
0.0 (µmol/L*h) 2.1 - 11.7 MPS-I
F3/P5 15.5 F + IH 102.68 3.3 - 13.7 
Alpha-L-
iduronidase 
0.1 (µmol/L*h) 2.1 - 11.7 MPS-I
F4/P6 8.3 M + HS 75.80 6.7 - 15.5 
Alpha-L-
iduronidase 
0.1 (µmol/L*h) 2.1 - 11.7 MPS-I
F5/P6 5.8 F + HS 96.91 7.9 - 16.2 
Alpha-L-
iduronidase 
0.2 (µmol/L*h) 2.1 - 11.7 MPS-I
F6/ P6 7.1 F - HS 95.68 6.7 - 15.5 
Alpha-L-
iduronidase 
0.0 (µmol/L*h) 2.1 - 11.7 MPS-I
F6/ P6 10.8 M - HS 95.05 3.3 - 13.7 
Alpha-L-
iduronidase 
0.0 (µmol/L*h) 2.1 - 11.7 MPS-I
F7/ P10 8.7 F + HS 56.70 6.7 - 15.5 
Alpha-L-
iduronidase 
0.1 (µmol/L*h) 2.1 - 11.7 MPS I
F5/ P11 9.3 M + HS 88.94 6.7 - 15.5 
Alpha-L-
iduronidase 
0.1 (µmol/L*h) 2.1 - 11.7 MPS-I
F8/ P12 7.6 M - HS 75.88 6.7 - 15.5 
Alpha-L-
iduronidase 
0.1 (µmol/L*h) 2.1 - 11.7 MPS-I
F9/ P13 4.9 M + HS 68.33 7.9 - 16.2 
Alpha-L-
iduronidase 
0.1 (µmol/L*h) 2.1 - 11.7 MPS-I
F10/ P14 7.1 M + HS 60.51 6.7 - 15.5 
Alpha-L-
iduronidase 
0.1 (µmol/L*h) 2.1 - 11.7 MPS-I
F11/ P15 10.8 M - HS 59.15 3.3 - 13.7 
Alpha-L-
iduronidase 
0.1 (µmol/L*h) 2.1 - 11.7 MPS-I
F12/ P16 10.9 F - HS 71.89 3.3 - 13.7 
Alpha-L-
iduronidase 
0.1 (µmol/L*h) 2.1 - 11.7 MPS-I
F13/ P17 6.9 M +  162.05 6.7 - 15.5 
Iduronate-2-
sulfatase 
0.1 (µmol/L*h) 9 - 29 MPS-II
























F16/ P21 15.5 F +  72.08 3.3 - 13.7 Arylsulfatase B 1.82 (µmol/L*h) 12 - 30 
MPS-
VI 
F17/ P22 9.3 M +  96.83 6.7 - 15.5 Arylsulfatase B 0.46 (µmol/L*h) 12 - 30 
MPS-
VI 
F18/ P23 14.8 F + IH 77.50 3.3 - 13.7 
Alpha-L-
iduronidase 
0.1 (µmol/L*h) 2.1 - 11.7 MPS-I
F18/ P24 5.7 F + IH 111.90 7.9 - 16.2 
Alpha-L-
iduronidase 
0.1 (µmol/L*h) 2.1 - 11.7 MPS-I
F18/ P25 1.5 M + IH 155.80 8.1 - 35. 
Alpha-L-
iduronidase 
0.1 (µmol/L*h) 2.1 - 11.7 MPS-I
F19/ P26 8.4 M +  78.00 6.7 - 15.5 
Iduronate-2-
sulfatase 
0.1 (µmol/L*h) 9 - 29 MPS-II
 
a - in MPSI disorder, b - reference values are age-dependent, c - performed at outside laboratory, enzymatic essays were performed in 
leucocytes, normal ranges are 10 - 45 nmol/mL/h, uGAGs - urinary Glycosaminoglycan, MPS - Mucopolysaccharidosis, + - Present, - - Absent, 
M - Male, F - Female. 
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Figure 1. Flow-chart for our laboratory diagnosis of MPS. 
 











Figure 2. Thin layer chromatography of standards GAGs and GAGs isolated from MPS diagnosed patients and healthy con-
trol. 
 
Urinary GAGs were isolated and chromatographed as described. Lane 1: QC, quality control (DS - dermatan sulfate, HS - heparan sulfate, 
C4S - chondroitin 4 sulfate, C6S - chondroitin 6 sulfate, and KS - keratan sulfate. Lane 2: patient with Hurler syndrome (MPSI). Lane 3: pa-
tient with Maroteaux-Lamy syndrome (MPS VI). Lane 4: patient with Hunter syndrome (MPSII). Lane 5: patient with Sanfilippo syndrome 
(MPS IIIB). Lane 6: healthy control. Lane 7: patient with micolipidosis III. Lane 8: patient on diagnosis with somatic features. 
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GAG evaluation, and TLC characterization modified 
and simplified to lead us to a specific enzyme activity 
assay using DBS samples. The use of GAG tests was 
useful for a quick screening of MPS among those pa-
tients suspected of suffering from MPS (IH/HS, II, III, 
or VI). The test enabled us to make a quick detection, 
confirmation, or exclusion of an MPS diagnosis, thus 
reducing the number of individuals requiring future test-
ing. This proved to be very helpful especially in rural 
areas of the country where consanguineous marriage is 
frequent. 
We used simultaneous quantitative and qualitative 
methods to reduce the chances of a false-negative result. 
The quantitative data were also used to normalize 
GAGs on TLC plates by adjusting for individual varia-
tion in excretion. This ensured uniform chromatograph-
ic behavior and facilitated estimation of the relative 
abundance of specific GAGs. The TLC analysis method 
allows the identification of an abnormal GAG pattern in 
all MPS and mucolipidosis patients and can help in the 
diagnosis of several other oligosaccharidoses based on 
abnormal patterns detected. It was not possible to distin-
guish MPS I from MPS II, on the basis of urinary GAG. 
Measuring both the iduronidase and iduronate-2-sulfa-
tase enzyme activities was therefore required to make a 
proper diagnosis. Since MPS I is the more common 
type in the North African populations [19,20], the 
iduronidase was assayed first. Maroteaux-Lamy syn-
drome (MPS VI) patients had a TLC pattern easily dis-
tinguished from MPS I and II with excretion of a large 
excess of DS and presence or absence of trace amounts 
of HS. In MPS III patients, a straightforward banding 
pattern was observed corresponding to HS, and two 
bands were observed in mucolipidosis III. Furthermore, 
it should also be emphasized that the TLC pattern pro-
vided a diagnostic orientation of the different types of 
MPS and/or mucolipidosis III/II, which directed us to 
focus on patients having symptoms consistent with mu-
copolysaccharidosis diseases and exhibiting characteris-
tics of oligosaccharidosis abnormal patterns on TLC 
analysis. 
Definitive diagnosis of inherited lysosomal storage dis-
eases is based on specific enzymatic assays performed 
on plasma, leukocytes, fibroblasts, and lately, dried 
blood spot samples. We confirmed the diagnosis of pa-
tients affected by several mucopolysaccharidosis types 
using DBS samples for appropriate enzyme assays. 
This method offers several advantages, including a sim-
ple and expedited sample collection, minimal invasive-
ness, reduced sample volume and easy sample handling 
and storage for extended periods. DBS samples can be 
used for assaying the activity of other lysosomal en-
zymes to reach a diagnosis. 
Clinical signs of different mucopolysaccharidosis types 
are variable from one disorder to another, but also in 
terms of the severity between patients suffering from 
the same MPS disorder. The total GAG levels in urine 
seem to be proportional to the severity of the symptoms. 
Indeed, among MPS I patients, three patients (P4, P12, 
and P14) who shared facial dysmorphism, joint stiff-
ness, hepatomegaly, umbilical hernia symptoms, and 
ear, nose, and throat (ENT) infections, presented differ-
ent clinical symptoms that could be related to the levels 
of GAG. Patient P4 (GAG 117.12) had severe central 
and peripheral nervous system involvement, cardiac 
symptomatology, and hearing loss. Patient P12 (GAG 
75, 88) had mild cardiac symptomatology, and patient 
P14 (GAG 60, 51) showed less severe symptoms. 
We performed enzyme activity assays on 3 patients 
clinically suspected with MPS IV, even though uGAG 
levels were normal, in order to avoid false-negatives. 
These three patients exhibited normal cognitive function 
and presented with chest deformity, short stature, and 
growth retardation. Both N-acetylgalactosamine-6-sul-
fatase and B-galactosidase were within normal ranges, 
and the diagnosis was excluded. These findings taught 
us to rely on the clinical presentation that should gener-
ate clinical suspicion of MPS IV like joint hypermobili-
ty (of the wrist in particular) as it is unique to MPS IV, 
kyphosis/gibbus, genu valgum, and shortness of breath 
[21]. 
In this study, we have used a targeted screening pro-
gram for children suspected of having MPS in our uni-
versity hospital. Our pilot study results allow us to sub-
mit proposals to implement the first national newborn 
screening (NBS) for MPS I. The key factors in recom-
mending MPS I for inclusion in NBS are the strongly 
improved efficacy of early-onset therapy with HSCT/ 
ERT, or ERT, making early diagnosis beneficial for the 
patient and society. 
Several limitations, however, should be acknowledged. 
First, the patients diagnosed in this study do not repre-
sent the distribution of MPS in the Moroccan popula-
tion. Second, DMB-based spectrophotometry can give 
rise to false negatives, especially in MPS III and IV [4]. 
In addition, in some cases; high levels of GAG may be 
due to other pathologies, such as diabetes, lupus, arthri-
tis, or mucolipidosis [18]. Finally, the method requires 
an investment of time (at least 4 days of handling are re-






An early and accurate diagnosis of MPS is critical not 
only in permitting disease-specific genetic counseling 
but also in guiding appropriate national supportive care 
and disease-specific therapy. This study is the first work 
diagnosing MPS in Morocco based on enzymatic activi-
ty assays in DBS specimens. This method, which is effi-
cient in diagnosing MPS subtypes, will offer several ad-
vantages to our laboratory in achieving its goal of be-
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